Impact of intravenous -lactam/macrolide versus -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia
Authors:
Open Access
- 5 March 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (5) , 1025-1033
Abstract
Guidelines recommend dual-therapy consisting of a β-lactam/macrolide (BLM) for hospitalized patients with community-acquired pneumonia. Nevertheless, the superiority over β-lactam-monotherapy (BL) remains unproven. Analyses from an observational study initiated by the German competence network CAPNETZ were performed. One thousand eight hundred and fifty-four patients were treated with either BL (49.0%) or BLM (51.0%). BLM therapy was associated with lower adjusted 14 day mortality [odds ratio (OR) 0.53; 95% confidence interval (CI): 0.30–0.94]. CRB65, neoplastic disease, age and nursing home residency were confirmed as independent predictors of death. Adjusted 14 day mortality risk was clearly reduced in patients with CRB65 = 2 (n = 411; OR 0.35; CI: 0.12–0.99) and CRB65 ≥ 2 (n = 519; OR 0.42; CI: 0.18–0.997). However, this could not be shown for adjusted 30 day mortality. Patients with CRB65 ≤ 1 showed low mortality (2.1%) without the influence of BLM. BLM therapy was associated with lower adjusted risk of treatment failure at 14 days (n = 1854; OR 0.65; CI: 0.47–0.89) and 30 days (OR 0.69; CI: 0.51–0.94) as well as in the subgroup of patients with CRB65 = 2 and CRB65 ≥ 2. This study suggests the superiority of BLM therapy in patients with CRB65 risk classes of 2 or higher on 14 day mortality. BLM therapy was also associated with lower risk of treatment failure.Keywords
This publication has 28 references indexed in Scilit:
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Guidelines for the management of adult lower respiratory tract infectionsEuropean Respiratory Journal, 2005
- Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent aloneEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal BacteremiaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Clinical Characteristics at Initial Presentation and Impact of Dual Therapy on the Outcome of Bacteremic Streptococcus pneumoniae Pneumonia in AdultsCanadian Respiratory Journal, 2004
- Impact of Initial Antibiotic Choice on Clinical Outcomes in Community-Acquired PneumoniaChest, 2003
- Addition of a Macrolide to a β‐Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower In‐Hospital Mortality for Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2003
- Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumoniaIntensive Care Medicine, 2002
- Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal PneumoniaArchives of internal medicine (1960), 2001
- Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumoniaClinical Therapeutics, 2000